Komori
Revision to earnings forecasts4526RIKEN VITAMIN CO.,LTD.Food

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

The interim consolidated results were released, and the full-year consolidated earnings forecast for the fiscal year ending March 2027 was revised from the figures announced on 13 May 2026. The new forecast calls for net sales of ¥101,000 million, operating income of ¥7,100 million, ordinary income of ¥7,600 million and net income attributable to owners of the parent of ¥7,800 million. The dividend forecast was also increased to ¥63 per share for the year-end dividend and ¥118 per share for the full year.

Worth reading
83Important
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full yearPrevious forecast published 13 May 2026
Net Sales—→101,000million
—
Operating profit—→7,100million
—
Ordinary income—→7,600million
—
Profit attributable to owners of the parent—→7,800million
—
Net income per share—→271.38yen and sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

The disclosure states that the figures announced on 13 May 2026 were revised, but no specific reason for the revision is provided.

Details and amount of extraordinary loss

An impairment loss on property, plant and equipment of ¥161 million, arising from the planned disposal of some operating assets of RIKEVITA(MALAYSIA)SDN.BHD., was recorded as a loss related to business restructuring. Total extraordinary losses for the interim period were ¥299 million.

Dividend forecast revisionThe year-end dividend forecast was increased to ¥63 per share and the full-year dividend forecast to ¥118 per share. The disclosure states that the dividend forecast was revised to increase the dividend.
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → ¥101,000 million
Operating profitNot disclosed → ¥7,100 million
Ordinary incomeNot disclosed → ¥7,600 million
Profit attributable to owners of the parentNot disclosed → ¥7,800 million
Net income per shareNot disclosed → 271.38 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Publication date of previous forecast13 May 2026
Reason for the revisionThe disclosure states that the figures announced on 13 May 2026 were revised, but no specific reason for the revision is provided.
Details and amount of extraordinary lossAn impairment loss on property, plant and equipment of ¥161 million, arising from the planned disposal of some operating assets of RIKEVITA(MALAYSIA)SDN.BHD., was recorded as a loss related to business restructuring. Total extraordinary losses for the interim period were ¥299 million.
Dividend forecast revisionThe year-end dividend forecast was increased to ¥63 per share and the full-year dividend forecast to ¥118 per share. The disclosure states that the dividend forecast was revised to increase the dividend.
Consolidated / non-consolidatedConsolidated
Items this document does not state (1)
Previous-period results

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The full-year earnings forecast is stated to have been revised from the figures announced on 13 May 2026, but no specific reason for the revision is provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | RIKEN VITAMIN CO.,LTD. (4526) timely disclosure | Komori